
|Videos|January 14, 2020
The Potential Impact of Targeting BCMA in R/R Multiple Myeloma
Multiple Myeloma
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5



































